Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
Posted in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in -
NAM Expert Briefing on Behavioral and Social Science Research Questions Raised By the Use of Biomarkers for Alzheimer’s Disease Diagnostics
On June 28 and 29, 2021, the National Academies of Sciences, Engineering, and Medicine convened an expert meeting that addressed behavioral and social science research questions raised by the use of biomarkers and other measures for pre-clinical AD/ADRD diagnosis
-
NAS Report Outlines Priorities for the Next Ten Years of Alzheimer’s Research
Julie Zissimopoulos participated on the committee tasked with developing the research agenda.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
Clinical Outcome Measure Crosswalks in Alzheimer’s Disease: A Systematic Review
A key challenge in studies that model outcomes, disease progression, and cost-effectiveness of existing and emerging dementia treatments is the lack of conversion criteria to translate, or ‘crosswalk’, scores on multiple measurement scales.
Categorized in -
Leveraging Behavioral Sciences for Dementia Care
Insights from the behavioral sciences may help doctors detect dementia earlier and develop more insightful care plans.
-
FDA’s Approval of Aducanumab Paves the Way for ‘More Momentous’ Alzheimer’s Breakthroughs
The FDA’s recent approval of the first disease-modifying therapy for Alzheimer’s will fuel the chances of even more breakthroughs.
-
Podcast: The Impact and Economics of Alzheimer’s
Julie Zissimopoulos recently spoke about her research using economic insights to better understand the impact of Alzheimer’s disease on individuals, families, caregivers, and society.
-
Association Between Exenatide Use and Incidence of Alzheimer’s Disease
Exenatide use is associated with a reduced incidence of AD among Medicare beneficiaries aged 65 years or older with type II diabetes.
Categorized in -
Information Session for Schaeffer Center Pilot Funding
Join us on Tuesday, January 12 to learn more about upcoming pilot funding opportunities through Schaeffer Center for Roybal Center for Behavioral Interventions in Aging, CeASES-ADRD and USC Alzheimer’s Disease Resource Center for Minority Aging Health Economics Research.